Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ABVC Biopharma Inc (ABVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: ABVC (3-star) is a STRONG-BUY. BUY since 93 days. Profits (559.15%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.02
1 Year Target Price $2.02
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 237.33% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.47M USD | Price to earnings Ratio - | 1Y Target Price 2.02 |
Price to earnings Ratio - | 1Y Target Price 2.02 | ||
Volume (30-day avg) 1 | Beta 0.19 | 52 Weeks Range 0.40 - 5.48 | Updated Date 07/9/2025 |
52 Weeks Range 0.40 - 5.48 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -503.56% |
Management Effectiveness
Return on Assets (TTM) -10.91% | Return on Equity (TTM) -42.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82445898 | Price to Sales(TTM) 156.33 |
Enterprise Value 82445898 | Price to Sales(TTM) 156.33 | ||
Enterprise Value to Revenue 162.17 | Enterprise Value to EBITDA -1.9 | Shares Outstanding 16981600 | Shares Floating 11364913 |
Shares Outstanding 16981600 | Shares Floating 11364913 | ||
Percent Insiders 16.47 | Percent Institutions 2.28 |
Upturn AI SWOT
ABVC Biopharma Inc
Company Overview
History and Background
ABVC Biopharma, Inc. (formerly American BriVision Corporation) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic solutions to treat unmet medical needs. Founded to develop ophthalmic products, it has broadened its focus to include oncology and other therapeutic areas.
Core Business Areas
- Drug Development: Focused on developing and commercializing therapeutic solutions for cancer and other unmet medical needs. Lead compound is ABV-1505 for pancreatic cancer.
- Medical Device: Develops and commercializes medical devices focused on ophthalmic treatments.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry, including Dr. Howard Doong (CEO). The organizational structure is typical of a small-cap biopharmaceutical company.
Top Products and Market Share
Key Offerings
- ABV-1505: ABV-1505 is a novel drug candidate in clinical development for the treatment of pancreatic cancer. Market share is currently 0% but aims to compete in the pancreatic cancer treatment market. Competitors include Eli Lilly, Roche, and Bristol Myers Squibb, which have approved pancreatic cancer treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. It is heavily regulated by agencies like the FDA.
Positioning
ABVC Biopharma is a small-cap company attempting to develop novel therapies in competitive markets. Its competitive advantage lies in its unique drug candidates and partnerships.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. ABVC Biopharma aims to capture a portion of this market with its cancer therapies. Exact TAM for ABV-1505 is dependent on successful clinical trials and FDA approval.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Small-cap size
Opportunities
- Successful clinical trial results
- FDA approval of drug candidates
- Potential for acquisitions or partnerships
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
Competitors and Market Share
Key Competitors
- LLY
- RHHBY
- BMY
Competitive Landscape
ABVC Biopharma faces significant competition from larger pharmaceutical companies with greater resources and established market presence. Its success hinges on differentiating its drug candidates and securing partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's development stage. Potential for growth depends on future FDA approvals.
Future Projections: Future growth projections depend on successful clinical trials and FDA approval of ABV-1505 and other drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include progressing ABV-1505 through clinical trials and seeking partnerships for commercialization.
Summary
ABVC Biopharma is a high-risk, high-reward biopharmaceutical company in the clinical stage, meaning it currently lacks a strong market position. Its primary asset, ABV-1505, offers hope for capturing market share contingent upon clinical trial success and regulatory approval. The company's financial health relies heavily on fundraising and strategic partnerships. Investors should carefully monitor clinical trial outcomes and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ABVC Biopharma Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2017-10-11 | CEO & Interim CFO Dr. Uttam Yashwant Patil Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.abvcpharma.com |
Full time employees 16 | Website https://www.abvcpharma.com | ||
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.